Literature DB >> 3080582

Mannitol pharmacokinetics and serum osmolality in dogs and humans.

J C Cloyd, B D Snyder, B Cleeremans, S R Bundlie, C H Blomquist, D J Lakatua.   

Abstract

The relationship between mannitol pharmacokinetics and changes in serum osmolality were studied in dogs and humans. Four human subjects each received between 0.5 and 0.7 g/kg of mannitol as an i.v. infusion given over 15 min. Intravenous bolus doses of 0.5, 1.0 and 1.5 g/kg were given to each of five animals. Serial determinations of serum osmolality and serum mannitol concentrations were then performed. Mannitol disposition was best described using a biexponential equation and assuming a two-compartment, open model with elimination from the central compartment. For human subjects, the mean (+/- S.D.) distribution half-life was 2.11 +/- 2.67 min and the elimination half-life was 71.15 +/- 27.02 min. The volume of distribution was 0.47 +/- 0.50 liters/kg and total body clearance was 7.15 +/- 10.23 ml X min-1 X kg-1. The disposition of mannitol in dogs is similar to that observed in humans. Mannitol clearance was independent of dose whereas the central compartment volume was significantly larger (P less than .005) in animals receiving the 1.5-g/kg dose. The volume change is probably due to a rapid, uncompensated shift of water from intracellular to extracellular space. There was a strong positive correlation (r = 0.90) between mannitol concentration and serum osmolality changes. However, neither maximum serum mannitol concentration nor maximum serum osmolality increased proportionately with dose. Only the 1.5-g/kg dose produced a sustained elevation of serum osmolality, confirming that larger doses are more likely to result in prolonged hypertonic dehydration.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3080582

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

Review 1.  Osmotic therapy: fact and fiction.

Authors:  Michael N Diringer; Allyson R Zazulia
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

2.  Variation in osmotic response to sustained mannitol administration.

Authors:  Salah G Keyrouz; Rajat Dhar; Michael N Diringer
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

3.  Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution.

Authors:  John Douglas Hoekman; Rodney J Y Ho
Journal:  AAPS PharmSciTech       Date:  2011-04-26       Impact factor: 3.246

4.  Mannitol decreases neocortical epileptiform activity during early brain development via cotransport of chloride and water.

Authors:  J Glykys; E Duquette; N Rahmati; K Duquette; K J Staley
Journal:  Neurobiol Dis       Date:  2019-02-01       Impact factor: 5.996

5.  Hemostatic and neuroprotective effects of human recombinant activated factor VII therapy after traumatic brain injury in pigs.

Authors:  Jun Zhang; Robert F Groff; Xiao-Han Chen; Kevin D Browne; Jason Huang; Eric D Schwartz; David F Meaney; Victoria E Johnson; Sherman C Stein; Rasmus Rojkjaer; Douglas H Smith
Journal:  Exp Neurol       Date:  2008-01-05       Impact factor: 5.330

Review 6.  Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.

Authors:  G Heinemeyer
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

Review 7.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

8.  Use of mannitol during neurosurgery: interpatient variability in the plasma and CSF levels.

Authors:  P Anderson; L Boréus; E Gordon; M Lagerkranser; A Rudehill; C Lindquist; G Ohman
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

9.  Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations.

Authors:  Matthew R Hart; Donovan J Anderson; Christopher C Porter; Tobias Neff; Michael Levin; Marshall S Horwitz
Journal:  PLoS Genet       Date:  2018-09-14       Impact factor: 5.917

10.  Sequential changes in urine production, glomerular filtration rate, and electrolyte excretion after mannitol administration.

Authors:  Gilad Segev; Cheryl Stafford; John Kirby; Larry D Cowgill
Journal:  J Vet Intern Med       Date:  2019-03-30       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.